Research
Hormonal
Weekly subcutaneous Semaglutide 2.4 mg results in a -13.7% body weight reduction.
Practitioners may consider Semaglutide as an effective weight loss therapy for women with preeclampsia.
StrongSupportsmedium confidence
Weekly subcutaneous Semaglutide 2.4 mg (-13.7% body weight)
Why this rating
Based on the mention of clinical trial data.
Source
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Ayesha Malik et al. · Journal of Hypertension · 2026
DOI 10.1097/hjh.0000000000004250
cohort
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →